Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Biondvax Pharma Ads (NQ: BVXV)
5.370 USD  -0.180 (-3.24%)
Streaming Delayed Price  /  Updated: 11:39 AM EDT, Oct 18, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,044
Open 5.550
Bid (Size) 5.380 (3)
Ask (Size) 5.650 (1)
Prev. Close 5.550
Today's Range 5.370 - 5.620
52wk Range 3.510 - 7.260
Shares Outstanding 6,535,489
Dividend Yield N/A
Performance
YTD
+11.52%
+11.52%
1 Month
-6.28%
-6.28%
3 Month
-16.74%
-16.74%
6 Month
-19.97%
-19.97%
1 Year
-1.29%
-1.29%
Top News
More News
BiondVax Receives €4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a phase 3 clinical stage biopharmaceutical company focused on developing and commercializing the M-001 clinical Phase 3 Universal Influenza Vaccine... Read More
from PR Newswire
BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced the... Read More
from PR Newswire
More News
Read More
BiondVax Announces Rights Offering Fully Subscribed at US$20 Million
from PR Newswire
First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
from PR Newswire
European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to €24million
from PR Newswire
Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan
from PR Newswire
BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process
from PR Newswire
BiondVax Announces First Quarter 2019 Financial Results
from PR Newswire
Kadimastem Announces Leadership Changes
from PR Newswire
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
from PR Newswire
BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
from PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
© Copyright FinancialContent Services, Inc.